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ABSTRACT 
Up to 40% of atrial fibrillation (AF) patients are asymptomatic.  Despite this, scarce data are 
available about asymptomatic AF, with regard to its clinical profile and relationship to 
cerebrovascular and cardiovascular risk.  Our objective was to conduct a systematic review 
and meta-analysis was to study the relationship between age and gender with asymptomatic 
AF and to establish whether patients with asymptomatic AF have a higher risk of death (all 
cause and cardiovascular) and stroke/systemic thromboembolism, when compared to 
symptomatic AF patients. 
After a comprehensive search, 6 studies (2 randomized clinical trials and 4 observational 
studies) were entered in the meta-analysis. 
Despite significant heterogeneity, our data show that the prevalence of females amongst 
asymptomatic AF group was significantly less compared to the symptomatic AF group (RR, 
0.57; 95%CI: 0.52-0.64). No difference in age between asymptomatic and symptomatic AF 
patients (P=0.72) was seen.   
No differences were found in all-cause death between patients with asymptomatic and 
symptomatic AF (RR, 1.38; 95%CI: 0.82-2.17), nor in cardiovascular death (RR, 0.85; 95%CI: 
0.53-1.36) or stroke/thromboembolism (RR, 1.72 95%CI: 0.59-5.08). 
Asymptomatic AF is more associated with male sex, irrespective of age. Both general and 
cardiovascular death risks as well as thromboembolic risk do not seem to be affected by the 
asymptomatic clinical status. Symptomatic status should not determine our approach to 
stroke prevention and other cardiovascular prevention therapies, amongst patients with AF. 
 
KEY WORDS: asymptomatic, symptomatic, atrial fibrillation, cardiovascular death, stroke. 
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INTRODUCTION 
 
Atrial fibrillation (AF) represents one of the most diagnosed supraventricular arrhythmia and 
its prevalence has been estimated to be 1-2% of the general population, with a progressive 
increase over the next few decades(1).  However, prevalence data of AF could have been 
underestimated due to the evidence that up to 40% of AF patients are asymptomatic(2). 
Despite this, scarce data are available about asymptomatic AF, with regard to its clinical 
profile and relationship to cerebrovascular and cardiovascular risk. 
 
Recent data from the EORP-AF Pilot Registry confirmed a high prevalence of asymptomatic AF 
patients, almost 40%(3).  Importantly, the EORP-AF data show that asymptomatic AF patients 
were at a higher risk for 1-year mortality compared to symptomatic AF patients(3). 
Conversely a substudy from the Atrial Fibrillation Follow-up Investigation of Rhythm 
Management (AFFIRM) trial suggested that there is no difference in mortality risk between 
asymptomatic and symptomatic AF patients(4).  Furthermore, trial data from the Cryptogenic 
Stroke and Underlying AF (CRISTAL AF) study show how could be possible to detect AF, 
regardless of symptoms, in about 4% in a cohort of patients diagnosed with cryptogenic 
stroke(5). 
 
An understanding of the clinical profile of asymptomatic AF patients and the impact on a 
higher thromboembolic risk could help plan established AF screening programs that could 
lead to earlier AF diagnosis and a reduction in the AF-related health burden(6). 
 
The aim of this systematic review and meta-analysis of available evidence was to study the 
relationship between age and gender with asymptomatic AF and to establish whether patients 
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with asymptomatic AF have a higher risk of death (all cause and cardiovascular) and 
stroke/systemic thromboembolism, when compared to symptomatic AF patients. 
 
 
METHODS 
 
Inclusion and Exclusion Criteria 
We included eligible studies published in English that focused on the comparison between 
asymptomatic AF and symptomatic AF, in line with the following criteria:   
i. Types of studies: randomized controlled trials or observational cohort studies;  
ii. Types of participants: AF patients divided into symptomatic and asymptomatic groups;  
iii. Types of outcome measures: endpoints of all mortality, cardiovascular death, stroke, or 
thromboembolism event; and 
iv. Other variables of interest: available baseline characteristics of AF patients according to 
the presence of symptoms 
Duplicate studies were excluded, as were certain publication types, such as conference 
abstracts, comments, editorials, case reports, etc.  
 
Search Strategy 
An extensive search for available studies was performed in three major medical literature 
databases: PubMed, Scopus and the Cochrane Database. Terms used for the search were as 
follows: (asymptomatic OR symptomatic) AND atrial fibrillation. The electronic search was 
restricted to peer-reviewed journals. Clinical trial databases and relevant reviews were hand 
searched for potentially relevant studies not identified in the electronic database search. 
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Data Extraction and Management 
All data retrieved from the PubMed, Scopus and Cochrane Database were managed using the 
commercial reference management software (Endnote X7, Thomson Reuters). Data extraction 
was performed by two reviewers (QX and MP) independently. The first sift-prescreening was 
completed through reading titles and then reading abstract and comprehensively reviewing 
full text to get hold of extra information did the second sift-selection. Data extracted from 
each study were, when available: mean age, gender distribution, follow-up time, overall all-
cause death, cardiovascular death, stroke and/or systemic thromboembolism. Disagreements 
were resolved by consensus or, if necessary, through discussion or consultation with a third 
reviewer (GL). 
 
The outcomes of interest included all-cause death, cardiovascular death, ischemic 
stroke/thromboembolism, quality of life, cardiovascular hospitalization, and AF progression. 
 
Quality and Risk of Bias Assessment 
A quality assessment process was performed to select the studies included in the meta-
analysis. The pre-specified criteria for the evaluation were: (i) the total number of patients 
enrolled in the study would have been more than 300; (ii) at least one year of expected 
follow-up; (iii) data available for crude outcomes taken separately. To be included in the 
meta-analysis each study had to meet all the criteria.  According to the design-specific 
recommended criteria, every study was evaluated for any potential risk of bias(7). 
 
Statistical Analysis 
Statistical analyses were performed using Review Manager Version 5.3 (Copenhagen, The 
Nordic Cochrane Centre, The Cochrane Collaboration, 2014). The endpoint events were 
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measured as dichotomous outcome variables and compared between asymptomatic AF and 
symptomatic AF groups. Gender was also defined as dichotomous variable to investigate the 
gender distribution difference between both groups. Relative risk (RR) or odds ratio (OR) 
were analyzed and presented with 95% confidence interval (CI) for the pooled differences. 
Data required for dichotomous variables were the numbers of events and total numbers for 
each study, while means and its standard deviations were analyzed for continuous variables. 
Cochrane’s chi-square test and were detected to quantify the statistical heterogeneity among 
included studies. Chi-square test evaluates whether the observed inconsistency may be due to 
chance alone. The I2 statistic describes the percentage of the variability in effect estimates due 
to heterogeneity rather than sampling error. A rough guide to interpretation of the I2 is as 
follows: 1) 0% to 25%: might not be important; 2) 25% to 50%: may present moderate 
heterogeneity; 3) 50% to 75%: may present substantial heterogeneity; 4) 75% to 100%: 
considerable heterogeneity.  
 
The appropriate statistical models, fixed-effect or random-effect models, were selected to 
ensure that the various statistics are estimated correctly. Subgroup analyses were performed 
when necessary. A P value<0.05 was considered significant difference.  
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RESULTS 
 
Based on our search, we identified 530 articles on the Cochrane Database, 3,347 on PubMed 
and 4,163 on Scopus. After checking for duplicates we reviewed a total of 4,163 articles. Two 
investigators reviewed all titles, obtaining a list of 35 articles to be reviewed by abstract and 
full text. Following this, 6 articles were found to be eligible for analysis (Figure 1). 
 
Study Characteristics 
Among these six studies, two trials were substudies from randomized controlled trials (RCTs), 
that is, the AFFIRM study(4) and the RAte Control versus Electrical cardioversion for 
persistent atrial fibrillation (RACE) study(8).  The remainder were observational cohort 
studies(3, 9–11).  
 
The baseline characteristics of all included studies are summarized in Table 1. A total of 2,534 
patients (717 female; 28.3%) with asymptomatic AF and 7,774 patients (3,082 female; 
39.6%) with symptomatic AF were included.  The mean length of follow-up ranged from 1 to 
9.9 years.  
 
In the study from Boriani et al. the only asymptomatic portion was 16.7% of the total study 
population, as identified (3). Characteristics on thromboembolic risk stratification and 
antithrombotic treatment between the two populations in the various studies are 
summarized in Table 2.  Due to the heterogeneity between the different study designs, these 
characteristics were not meta-analyzed.  
 
Risk of bias assessment 
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Every study was evaluated for any potential risk of bias(7).  All the articles included in the 
meta-analysis had an overall low risk of bias, as reported in Table 3. Risk of bias for every 
domain was defined as high, low or unclear. Overall bias risk for each study was determined 
with a risk level of at least 4 out of 5 domains. 
 
Data synthesis 
(a) Gender differences  
In the present meta-analysis, female gender was defined as a dichotomous variable to be 
compared between asymptomatic and symptomatic AF groups. Considerable heterogeneity 
was measured when we performed pooled analyses of all six included studies, as reflected by 
I2 as high as 70%. Given that the different type of studies can potentially be associated with 
the variability between studies, subgroup analyses were carried out accordingly. In addition, a 
random effects model was used for meta-analysis due to the high heterogeneity.  
 
The comparison of gender differences between two groups is shown as a forest plot in Figure 
2. The I2 statistics were 52% and 37% in each subgroup analysis, representing moderate 
heterogeneity, which can be acceptable. The prevalence of females amongst asymptomatic AF 
patients was significantly less compared to the symptomatic AF group (RR, 0.57; 95%CI: 0.52-
0.64).  
 
(b) Age differences 
When comparing the age difference between asymptomatic and symptomatic AF patients, five 
of all included studies were included for pooled analysis, except for the EURO-AF pilot general 
registry that only reported the median of age for both groups. When data were pooled across 
the remaining five studies, including mean age and SD, moderate heterogeneity was evident 
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significant, with no difference in age between asymptomatic and symptomatic AF patients 
(P=0.72) (Figure 3).    
 
(c) All cause death 
All-cause mortality was available in four of these included studies. The heterogeneity of these 
studies was considerable, as reflected by I2 statistic as high as 75%, and this, a random effect 
model was adopted for pooled analysis. No difference was found in all-cause death between 
patients with asymptomatic and symptomatic AF (RR, 1.38; 95%CI: 0.82-2.17) as shown in 
Figure 4. Given the high heterogeneity, the interpretation of this result should be more 
cautious.     
 
(d) Cardiovascular death 
Among all included studies, four reported the outcome of CV death. When these data were 
extracted for pooled analysis, no significant difference between asymptomatic and 
symptomatic AF patients (RR, 0.85; 95%CI: 0.53-1.36) was seen, as shown in Figure 5. The I2 
statistic of 0% represented very low heterogeneity, indicating that these studies are regarded 
homogeneous.  
 
(e) Stroke/thromboembolism   
All included studies were divided into two subgroups (RCT, observational studies) for the 
pooled analysis due to the high heterogeneity. No difference of stroke/TE occurrence was 
found in the RCT subgroup, along with an I2 statistic of 0%. In the analysis of observational 
studies, two individual studies has shown that the risk of stroke/TE was higher in patients 
with asymptomatic AF (RR, 8.89; 95%CI: 3.38-23.37 and RR, 2.19; 95%CI: 1.17-4.11, 
respectively). However, the overall pooled estimate demonstrated no significant difference in 
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stroke/TE between both groups (RR, 1.72 95%CI: 0.59-5.08) as shown in Figure 6. The high 
heterogeneity should be taken into account when interpreting this result. 
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DISCUSSION  
 
In this systematic review and meta-analysis, our data suggest that male sex is significantly 
associated with asymptomatic AF, whilst no difference was seen in age.  Second, 
asymptomatic AF was similar to symptomatic AF in the risk of overall risks of death, CV death 
or stroke/thromboembolic events. 
 
Gender-related differences in the epidemiology, clinical characteristics and management of AF 
patients are well described(12–14). There is usually a higher incidence of AF in men than in 
women(15). However, women with AF are at higher risk of stroke and thromboembolism, 
particularly elderly women(16).  Treatment of AF also varies among men and women, with 
regard to antithrombotic therapy and the choice of rate or rhythm control(12).  
 
In the present meta-analysis, a lower prevalence of asymptomatic AF was observed in women 
than in men, as reflected by RR of 0.57. This indicates that female patients were more 
symptomatic compared with males, as documented in various studies(17–19). In the EORP AF 
Pilot Registry, palpitations and fear/anxiety were more common symptoms in female 
individuals, while no difference was found in other symptoms (e.g. dyspnoea, chest pain, 
fatigue, etc.) between both genders(18).  Indeed, our results may indirectly reflect gender 
differences in the management of AF, regarding rate control or rhythm control. In EORP AF 
female AF patients with typical AF symptoms were more likely to receive rate control(18). 
 
No statistical difference was found when we compared the age between asymptomatic and 
symptomatic AF patients. The prevalence of AF rises with increasing age(1) and given the 
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ageing general population, the number of AF patients is estimated to increase greatly(15). No 
previous study has reported the association between age and symptoms among AF patients.   
 
Data coming from two major previous studies, both inserted in this present meta-analysis, 
had contrasting data on differences in mortality risk between asymptomatic and symptomatic 
patients. Boriani et al.(3) documented that asymptomatic AF patients had a significantly 
higher occurrence of death when compared with symptomatic patients. Conversely Flaker et 
al.(4) found that even after adjusting for previous major CV conditions, no difference in the 
risk of death was present between asymptomatic and symptomatic AF patients (hazard ratio 
1.07, 95% CI 0.79-1.46, p = 0.67). Our data confirm that it’s not possible to highlight any 
profound difference in overall mortality between patients with asymptomatic and 
symptomatic AF. 
Even when focused on CV mortality, no difference was seen, despite AF patients having a high 
cardiovascular risk profile(20, 21). This risk is evident regardless of the symptom status, 
perhaps suggesting how AF patients need to be comprehensively treated, independently of 
symptomatic status. 
 
The present meta-analysis underlines how the risk of thromboembolic events should not be 
based on the clinical status.  Recent data on anticoagulant therapy in asymptomatic AF 
patients from the EORP AF Pilot Registry show that asymptomatic AF patients are similarly 
treated with anticoagulant therapy, compared to the symptomatic ones; however, if they had 
at least one symptomatic episode, fully asymptomatic patients were still significantly less 
treated with oral anticoagulants than those patients with one symptomatic episode(3).   
Indeed, fully asymptomatic AF patients were more likely treated with antiplatelet therapy 
regardless the higher thromboembolic risk(3).   
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Limitations 
The principal limitation of the present meta-analysis is the reported high heterogeneity 
between the studies enrolled. This reflects the observational nature of four out of six studies 
selected. Even if this could affect the reliability of our results, the presence of observational 
studies still gives us insight into the “real-life” situation on the clinical burden of 
asymptomatic AF and its natural history. 
 
In conclusion, asymptomatic AF is more associated with male sex, irrespective of age. Both 
general and cardiovascular death risks as well as thromboembolic risk do not seem to be 
affected by the asymptomatic clinical status. Symptomatic status should not determine our 
approach to stroke prevention and other cardiovascular prevention therapies, amongst 
patients with AF. 
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FIGURE LEGENDS 
 
 
Figure 1: Study selection process. 
Figure 2: A comparison of symptomatic and symptomatic AF in female patients  
(Event numbers refer to patient numbers). 
Figure 3: Age differences comparing patients with asymptomatic AF and those with 
symptomatic AF. 
Figure 4: All-cause death in patients with asymptomatic AF and those with symptomatic AF. 
Figure 5: Cardiovascular death in patients with asymptomatic AF and those with 
symptomatic AF. 
Figure 6: Comparison of TE events in patients with asymptomatic AF and those with 
symptomatic AF. 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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Table 1: Characteristics of the studies comparing asymptomatic and symptomatic AF 
patients. 
 
Legend: AF= Atrial Fibrillation; CV= Cardiovascular; TE= Thromboembolism; YRS= Years. 
  
STUDY DATA 
SOURCE 
ASYMPTOMATIC AF SYMPTOMATIC AF  FU 
(Years
) 
OUTCOMES 
N Age Femal
e (N) 
N Age Femal
e (N) 
Flaker, 
GC  
2005 (4) 
AFFIRM Trial 481 70±8.3 111 3,57
6 
69.7±9 1481 3.5 
(mean) 
All death; 
Stroke 
Komatsu
, T 
2010 
(11) 
Retrospectiv
e study 
45 66.6±11.
8 
10 289 67.0±9.9 95 5.0±0.
9 
CV death; TE 
Potpara, 
T 
2013 (9) 
Observationa
l study 
146 53.1±13.
1 
24 954 52.6±12.
1 
328 9.9±6.
1 
All death;  
CV death; TE;  
AF 
progression 
Boriani, 
G  
2014 (3) 
EORP-AF 
Pilot Registry 
1,23
7 
72 
(median) 
433 1,88
2 
68 
(median) 
826 1.0±0.
1 
All death; TE;  
CV 
hospitalizatio
n 
Rienstra, 
M 
2014 (8) 
RACE Trial 157 67±9 44 365 69±9 148 2.3±0.
6 
QOL; CV 
death; 
TE 
Senoo, K  
2014 
(10) 
Shinken 
Database 
468 61.2±12.
6 
95 708 61.5±13.
5 
206 3.3±2.
5 
Ischemic 
stroke; CV 
death;  
All death;  
AF 
progression 
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Table 2: Thromboembolic risk and antithrombotic treatment distribution in the 
studies comparing asymptomatic and symptomatic AF patients. 
 
Legend: AF= Atrial Fibrillation; CV= Cardiovascular; NA= Not Available; TE= 
Thromboembolism; VKAs= Vitamin K Antagonist; YRS= Years. 
  
STUDY ASYMPTOMATIC AF SYMPTOMATIC AF  
Thromboembolic 
Risk 
Antithrombotic 
Treatment  
[Drug/Type (%)] 
Thromboembolic Risk Antithrombotic 
Treatment 
[Drug/Type (%)] 
Flaker, 
GC  
2005 (4) 
NA Aspirin (21) 
Warfarin (91) 
NA Aspirin (27) 
Warfarin (84) 
Komatsu, 
T 
2010 
(11) 
CHADS2 
1.63 ± 1.27 (Mean) 
Aspirin (42) 
Warfarin (24) 
CHADS2 
1.14 ± 1.18 (Mean) 
Aspirin (28) 
Warfarin (24) 
Potpara, 
T 
2013 (9) 
CHA2DS2-VASc 
≥2 (32.9%) 
Aspirin (47.9) 
VKAs (40.4) 
CHA2DS2-VASc 
≥2 (36.5%) 
Aspirin (48.6) 
VKAs (21.3) 
Boriani, 
G  
2014 (3) 
CHA2DS2-VASc 
≥2 (84.7%) 
Antiplatelets (32.3) 
Oral Anticoagulants 
(83.0) 
CHA2DS2-VASc 
≥2 (79.7%) 
Antiplatelets (35.5) 
Oral Anticoagulants 
(81.2) 
Rienstra, 
M 
2014 (8) 
CHADS2 
1.2 ± 1.1 (Mean) 
NA CHADS2 
1.7 ± 1.1 (Mean) 
NA 
Senoo, K  
2014 
(10) 
CHA2DS2-VASc 
≥2 (40.0%) 
Antiplatelets (40.9) 
Oral Anticoagulants 
(33.8) 
CHA2DS2-VASc 
≥2 (47.0%) 
Antiplatelets (39.2) 
Oral Anticoagulants 
(42.4) 
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Table 3: Risk of bias evaluation 
 Flaker, 
GC  
2005 (4) 
Komatsu, 
T 
2010 (11) 
Potpara, 
T 
2013 (9) 
Boriani, G  
2014 (3) 
Rienstra, 
M 
2014 (8) 
Senoo, K  
2014 
(10) 
Selection Bias* L L L L L L 
Performance Bias# L L L L L U 
Attrition Bias¶ L L L L L L 
Detection Bias§ L L L L L L 
Reporting Bias^ L L L L L L 
Overall Risk of Bias L L L L L L 
 
Legend: L= Low; U= Unclear. 
* Randomization, allocation concealment, sequence generation, control for confounders in 
cohort studies;  
# Fidelity to protocol, unintended interventions or co-interventions; 
¶ Incomplete outcome data, intention-to-treat analysis, and completeness of follow-up; 
§ Blinding of outcome assessors, especially with subjective outcome assessments, bias in 
inferential statistics, valid and reliable measures;  
^ Selective outcome reporting evaluation by comparing study report and (a) protocol or (b) 
outcomes prespecified in methods.  
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HIGHLIGHTS 
 Asymptomatic atrial fibrillation (AF) is more associated with male sex, irrespective of 
age.  
 Asymptomatic clinical status doesn’t seem to affect death risk as well as 
thromboembolic risk. 
 Clinical status shouldn’t determine our approach to pharmacological prevention 
strategies. 
